Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Titration of BIAsp 30 + Metformin in T2D
NCT01589653Phase 4Completed
- Sponsor
- Novo Nordisk
- Start
- May 2012
- Primary completion
- Jul 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 6
01
Overview
Phase 4, randomised, open-label trial of biphasic insulin aspart in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Change in HbA1c From Baseline at 20 weeks. Started May 2012; status: completed.
02
Drugs
biphasic insulin aspart
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01589653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01589653.